A Medical Device Daily

Cyberonics (Houston), the troubled developer of vagus nerve stimulation therapy, yesterday reported receiving a third staff determination letter from the Nasdaq indicating that it fails to comply with the filing requirement for continued listing as a result of the delay in filing its report for its fiscal quarter ended Oct. 27, 2006, and that its securities are subject to delisting. The letter advises the company to present its views concerning this additional deficiency no later than today.

Cyberonics said it would do so but gave no assurance of continued listing.

• Healthcare Technologies (Petach Tikva, Israel) reported receiving notice from the NASDAQ that it has regained compliance with the exchange’s “bid price” rule, because the closing bid price per share for its ordinary shares has been above $1 per share for more than 10 consecutive trading days. As a result, the company said it has decided not to proceed with its proposed reverse stock split of ordinary shares. Healthcare Technologies, through it subsidiaries and affiliate, Gamidor Diagnostics, Danyel Biotech, and Savyon Diagnostics, manufactures clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point-of-care sites.

• HEI (Minneapolis) said it has submitted an application to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Markets. On Dec. 5, the company received a notice from the NASDAQ indicating that its stockholders’ equity does not comply with the minimum $10 million stockholders’ equity requirement for continued listing on The NASDAQ Global Market. HEI manufactures microelectronics, subsystems, systems, connectivity and software solutions for OEMs.